GSA Capital Partners’s Actinium Pharmaceuticals ATNM Stock Holding History

GSA Capital Partners’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-56,673	Closed	-$341K	–	1397
2021 Q4	$341K	Sell	56,673 -11,532	-17%	-$86.5K	0.04%	851
2021 Q3	$604K	Buy	68,205 +21,108	+45%	+$147K	0.06%	585
2021 Q2	$373K	Buy	47,097 +8,091	+21%	+$63.5K	0.04%	807
2021 Q1	$297K	Buy	+39,006	New	+$331K	0.05%	652
2020 Q4	–	Sell	-13,823	Closed	-$134K	–	1197
2020 Q3	$134K	Buy	+13,823	New	+$152K	0.02%	1087
2016 Q3	–	Sell	-4,647	Closed	-$247K	–	1758
2016 Q2	$247K	Buy	+4,647	New	+$259K	0.01%	1484

Other funds holding ATNM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GSA Capital Partners's ATNM Position: Q1 2022 in Review

GSA Capital Partners sold out of Actinium Pharmaceuticals (ATNM) in Q1 2022, closing a stake of 56,673 shares — an estimated $341K sold.

GSA Capital Partners first reported a position in ATNM in Q2 2016 and held it in 6 quarters. The position peaked at $604K in Q3 2021. 38 funds tracked by Wall St. Rank hold ATNM as of Q1 2022.

GSA Capital Partners reported no remaining Actinium Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
GSA Capital Partners sold 56,673 Actinium Pharmaceuticals shares in Q1 2022, an estimated $341K.
GSA Capital Partners first reported a position in Actinium Pharmaceuticals in Q2 2016 and held it in 6 quarters.
GSA Capital Partners's Actinium Pharmaceuticals position peaked at $604K in Q3 2021.
38 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2022.

Based on GSA Capital Partners's 13F filing for Q1 2022, filed 11 May 2022.